Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

scientific article published on 05 October 2020

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41591-020-1082-2
P698PubMed publication ID33020648

P50authorKeith FlahertyQ6384357
Dirk SchadendorfQ32649390
Antoni RibasQ32649604
Reinhard DummerQ32650033
Caroline RobertQ41784107
Georgina V. LongQ42947998
Hussein TawbiQ89392894
Paolo Antonio AsciertoQ89457677
P2093author name stringCeleste Lebbé
Mario Mandalà
Victoria Atkinson
Daniel Gusenleitner
Erika Richtig
Jan C Brase
Ana Arance
Naoya Yamazaki
Catarina D Campbell
Aisha Masood
Paul D Nathan
Eduard Gasal
Neha Pakhle
P2860cites workGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profilesQ24536351
Fast and accurate short read alignment with Burrows-Wheeler transformQ24653853
Acquired and intrinsic resistance in cancer immunotherapyQ26827701
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataQ27860742
edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataQ27860819
A framework for variation discovery and genotyping using next-generation DNA sequencing dataQ29547262
HTSeq--a Python framework to work with high-throughput sequencing dataQ29614489
STAR: ultrafast universal RNA-seq alignerQ29615052
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short readsQ29617402
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesQ34327021
The Molecular Signatures Database (MSigDB) hallmark gene set collectionQ34509167
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialQ34670965
Molecular signatures database (MSigDB) 3.0.Q35019708
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanomaQ36612452
Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads.Q37695453
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in MelanomaQ39013253
Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Q39043132
PureCN: copy number calling and SNV classification using targeted short read sequencing.Q39079807
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialQ40182275
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.Q40454933
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Q41950059
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.Q45953253
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.Q46394566
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.Q47573421
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanomaQ47573472
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.Q52681406
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.Q52888037
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.Q54380273
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyQ57472982
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic MelanomaQ64248097
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialQ89481181
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaQ90342370
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Q90369153
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.Q91013491
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitorsQ91295682
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyQ91503293
Immunological effects of BRAF+MEK inhibitionQ91523732
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyQ92182785
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaQ92415695
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsQ92573076
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaQ92573085
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaQ92573091
P433issue10
P921main subjectbiomarkerQ864574
P304page(s)1557-1563
P577publication date2020-10-05
P1433published inNature MedicineQ1633234
P1476titleCombined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
P478volume26

Search more.